Business Wire

Kao Revamps Cosmetics Business Strategy to Accelerate Growth

29.9.2025 04:00:00 CEST | Business Wire | Press Release

Share

On September 19, 2025, Kao Corporation (TOKYO:4452) announced a revamp of its Cosmetics Business strategy to accelerate growth. Positioned as a key growth driver within the Kao Group, the Cosmetics Business is targeting net sales of 400 billion yen and an operating margin of 15% at the earliest feasible timing after 2030. As a milestone toward this ambition and in alignment with the medium-term management plan “K27,” Kao will pursue a set of strategic initiatives to drive further expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250928711113/en/

Six focus brands of Kao Cosmetics

  • Kao will divide the six brands poised for global growth into three distinct overseas expansion models, sharpening brand positioning and enhancing competitiveness in the global market.
  • Leveraging its broad technological assets as a diversified chemical manufacturer, Kao will apply its distinct fundamental technologies across categories and brands.
  • By integrating human expertise with AI, the company will maximize sales capabilities, further streamline supply chain management, and reduce fixed costs to strengthen business foundation.

Growth Strategy for Six Focus Brands

Kao will position SENSAI, MOLTON BROWN, KANEBO, SOFINA, Curél, and KATE as its focused global growth brands. The company will accelerate overseas expansion in markets where these brands address consumer needs and can leverage Kao’s extensive resources and expertise.

Japan-Origin model:

Curél, Japan's number one brand for sensitive skin care*1, is accelerating its expansion in the European market. Backed by more than 40 years of expertise in dry, sensitive skin and over 25 years of ceramide research, Curél entered Europe in 2019 and has since gained strong traction. In the first half of 2025, sales in the UK rose 70% year-on-year, underscoring robust demand. Leveraging the proven efficacy of its “ceramide care,” Kao will expand Curél’s store presence in Europe by six times, with a goal of generating 50% of total brand sales outside Japan by 2027.
*1 INTAGE SRI+ Sensitive Skin Care Market – Value Share, July 2024 to June 2025

Europe-Origin Model:

Kao is expanding its luxury brands SENSAI and MOLTON BROWN, both of which embody distinctive aesthetics and philosophies that have strongly resonated with consumers in Europe’s luxury segment. The strategy now focuses on capturing growth in the rapidly expanding Asian luxury market. Through “Integrated operations” that manages Asia as one market for global shoppers, Kao aims to increase SENSAI sales in Asia (including Japan) by 150% and MOLTON BROWN sales by 100% by 2027, compared with 2024 levels.

Asia Model:

This model adapts brand values developed in Japan to meet the unique characteristics of Asian markets. Thailand, with its strong cultural affinity to Japan in areas such as makeup and anime, will serve as the pilot market. Kao will concentrate on the KANEBO and KATE brands to establish a successful blueprint for regional rollout, targeting sales growth of 150% in Thailand by 2027 compared with 2024 levels. In parallel, Kao will reposition SOFINA, unifying its sub-brands under the SOFINA umbrella. Since its establishment in 1982, SOFINA has built a strong presence in Japan with its science-driven approach to skincare and makeup. By 2027, Kao aims to increase SOFINA sales in Asia (excluding Japan) by approximately 50%.

Improving Soundness by Enhancing Earning Power and Streamlining Fixed Costs

Kao will reinforce profitability and long-term growth by focusing resources on the six brands, while also strengthening business foundation.

The company plans to implement its fundamental technologies across various brands and categories. By integrating its extensive technological assets—spanning dermatology, bioscience, chemicals, and production processes—Kao will achieve effective investment by sharing of strong technology-driven differentiation. This strategy is unique to a diversified chemical manufacturer like Kao.

Additionally, by leveraging the expertise of its workforce and incorporating digital capabilities and artificial intelligence, Kao intends to maximize sales potential and enhance supply chain management efficiency. This will lead to further fixed cost reductions and establish a more resilient business structure.

Leadership and Vision

These initiatives will be led by Tomoko Uchiyama, Executive Officer and President of Global Consumer Care - Cosmetics Business, who assumed her role in January 2025. Having successfully transformed Kao’s hair care business, Uchiyama will now apply her expertise to drive the growth and renewal of the Cosmetics Business.

Uchiyama commented:
“Our Cosmetics Business has the flexibility to respond to changing times and market dynamics with a diverse portfolio of brands. By combining this agility with the broad and solid foundation of the Kao Group, we will serve as a pioneer within the company in advancing globalization and accumulating expertise. To that end, we will pursue a strategy centered on the six brands, aiming to establish a strong earnings base by 2027 through both growth initiatives and structural reforms. Building on this foundation, we will target sustainable growth beyond, striving to achieve ‘Global Sharp Top’ with a brand portfolio that blends scientific evidence with sensorial beauty.

About Kao

Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack laundry detergent, Bioré and Jergens skin care products, Laurier sanitary products, Curél, SENSAI, and MOLTON BROWN cosmetics, and Oribe hair care products, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,630 billion yen in annual sales. Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation. As an enterprise that provides products people use on a daily basis, the Kao Group takes responsibility to actively reduce the environmental footprint of its products throughout the product lifecycle. This is laid out in Kao’s ESG strategy, the Kirei Lifestyle Plan, which launched in 2019.
Please visit the Kao Group website for additional information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250928711113/en/

Contacts

Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye